NantHealth Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Rao Naseem

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	7.9yrs

Recente managementupdates

Recent updates

CEO

Rao Naseem (56 yo)

less than a year

Tenure

Dr. Rao Haris Naseem, FACC, FHRS, M.D., is CEO & Director of NantHealth, Inc. since September 07, 2023. He has served as Wellvana Health LLC's Board Member and Executive Vice President since April of 2022....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Patrick Soon-Shiong	Founder & Chairman	13.3yrs	geen gegevens	0.41% € 47.3k
Bob Petrou	Chief Financial Officer	5.2yrs	US$545.78k	0% € 0
Ronald Louks	Chief Development Officer	less than a year	US$828.80k	0.055% € 6.3k
Rao Naseem	CEO & Director	less than a year	geen gegevens	geen gegevens
Lauren Schiegg	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Chad Brodeur	Vice President of Sales	less than a year	geen gegevens	geen gegevens
Arlyn Small	Chief People Officer	2.8yrs	geen gegevens	geen gegevens
Keith Krebs	Senior Vice President of Product Development	6.1yrs	geen gegevens	geen gegevens
Mark Mozley	Senior Vice President of Sales & Marketing of The OpenNMS Group	1.8yrs	geen gegevens	geen gegevens
Tiffany Avery	Chief Medical Officer	2.3yrs	geen gegevens	geen gegevens
Brandon Villery	Corporate Secretary	no data	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NEL0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Patrick Soon-Shiong	Founder & Chairman	13.3yrs	geen gegevens	0.41% € 47.3k
Rao Naseem	CEO & Director	less than a year	geen gegevens	geen gegevens
Michael Blaszyk	Independent Director	8.3yrs	US$155.76k	0.036% € 4.2k
Kirk Calhoun	Independent Director	7.5yrs	US$175.76k	0.036% € 4.2k

7.9yrs

Gemiddelde duur

70.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NEL0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.9 jaar).

NantHealth Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

NantHealth, Inc. Announces Executive Changes

Insufficient new directors

Recent updates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

Summus Holdings Engages in Discussions with NantHealth

NantHealth, Inc. Announces Executive Changes

Nant Capital Engages in Discussions with NantHealth

Nant Capital Engages in Discussions with NantHealth

NantHealth, Inc. announced delayed 10-Q filing

NantHealth, Inc.(NasdaqGS:NH) dropped from S&P TMI Index

NantHealth Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Publicly Held Shares Requirement

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

NantHealth Receives Written Notice from Nasdaq Stating the Company Has Not Complied with the Public Float Requirement Prior to the Expiration of the Compliance Period

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

NantHealth, Inc. Receives Written Notice from Nasdaq

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.14 loss in 1Q 2021)

NantHealth, Inc. to Report Q1, 2022 Results on May 05, 2022

NantHealth, Inc. Receives Notice from the Nasdaq Stock Market LLC

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

NantHealth, Inc. to Report Q4, 2021 Results on Feb 24, 2022

NantHealth, Inc. Announces Not Stand for Re-Election of Michael S. Sitrick as Member of the Board Directors

Third quarter 2021 earnings released: US$0.094 loss per share (vs US$0.099 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.43 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.081 loss in 1Q 2020)

NantHealth, Inc. Launches Eviti Connect for Autoimmune Diseases

Founder recently bought €4.2m worth of stock

Founder recently bought €4.2m worth of stock

NantHealth, Inc. announced that it expects to receive $137.5 million in funding from Nant Capital, LLC, Highbridge Capital Management, LLC

Chief Operating Officer recently sold €249k worth of stock

Full year 2020 earnings released: US$0.80 loss per share (vs US$0.57 loss in FY 2019)

Revenue misses expectations

NantHealth, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €3.88

NantHealth, Inc. and Sesame Announces Collaboration to Help Providers Increase Productivity and Better Serve Patients

New 90-day high: €3.41

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NantHealth, Inc. and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Revenue beats expectations

Third quarter 2020 earnings released: US$0.099 loss per share

New 90-day low: €1.75

NantHealth, Inc. to Report Q3, 2020 Results on Nov 05, 2020

NantHealth, Inc. to Report Q2, 2019 Results on Aug 08, 2019

NantHealth, Inc. Enhances Interoperability of the Navinet Open Platform with Expanded API Capabilities

NantHealth, Inc. Rolls Out Navinet AllPayer Platform Nationally

New 90-day low - €2.23

First half earnings released

NantHealth, Inc. to Report Q2, 2020 Results on Aug 06, 2020

NantHealth, Inc. (NasdaqGS:NH) acquired The OpenNMS Group, Inc. Cambridge Equities, LP.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd